Skip to main content
You're viewing the free public version. Create a free account for full research and member tools. Join free
Research Abstract In Vitro Study

A compound found within Asian and American ginseng known as Ginsenoside Rg3 inhibits colorectal tumor growth.

Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ß-catenin signaling.

0:00 / 0:00
0:00 / 0:00

Sign in to access this feature

Create a free account or sign in to use AI summaries, listen to articles, download PDFs, and save to your library.

218 views
Share:

Abstract

Colorectal cancer (CRC) is one of the most common and deadly malignancies in the world. Most CRCs are initiated by aberrant activation of the Wnt/ß-catenin signaling pathway. Despite the advances in its early diagnosis, optimized surgical approaches, and chemotherapies, the clinical management of advanced CRC requires effective adjuvant agents. Ginsenoside Rg3 is a single compound isolated from American ginseng (Panax quinquefolius L., Araliaceae) and Asian ginseng (Panax ginseng C. A. Meyer). We investigated the anticancer activity of Rg3 on colon cancer cells and its potential molecular mechanism behind Rg3's anticancer activity. We found that Rg3 inhibits cell proliferation and viability of cancer cells in vitro. This inhibitory effect of Rg3 is, at least in part, mediated by blocking nuclear translocation of the ß-catenin protein and hence inhibiting ß-catenin/Tcf transcriptional activity. Allelic deletion of the oncogenic ß-catenin in HCT116 cells renders the cells more sensitive to Rg3-induced growth inhibition. Using the xenograft tumor model of human colon cancer, we have demonstrated that Rg3 effectively inhibits the growth of tumors derived from the human colon cancer cell line HCT116. Histologic examination revealed that Rg3 inhibits cancer cell proliferation, decreases PNCA expression and diminishes nuclear staining intensity of ß-catenin. Taken together, our results strongly suggest that the anticancer activity of Rg3 may be in part caused by blocking the nuclear translocation of ß-catenin in colon cancer cells. This line of investigation may lead to the development of novel therapies in which Rg3 can be used as an effective adjuvant agent for the clinical management of colorectal cancers.

Affiliation

Department of Pharmacology and the Key Laboratory of Diagnostic Medicine designated by Chinese Ministry of Education, Chongqing Medical University, Chongqing, P.R. China.

External References

PubMed ID:
21152855

Comments

Sign in or create a free account to join the conversation.

Sign in to comment

Be the first to comment.

More Research Abstracts

View All Abstracts

Trusted By Professionals and Teams:

The National Health Federation
Stand For Health Freedom
Global Healing Institute
Global Wellness Forum
MAHA Action
Myers Detox
Natural News
Mercola.com

Unlock Evidence-Based Health Research

Join 500,000+ members accessing 10,000+ natural health topics.

Subscribe to our informative Newsletter & Receive

Cancer Fighting Foods Ebook

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of GreenMedInfo or its staff.